Knight Therapeutics (TSX:GUD) Long-Term Debt : C$44.0 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Long-Term Debt?

Knight Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2023 was C$44.0 Mil.

Knight Therapeutics's quarterly Long-Term Debt declined from Jun. 2023 (C$51.4 Mil) to Sep. 2023 (C$49.7 Mil) and declined from Sep. 2023 (C$49.7 Mil) to Dec. 2023 (C$44.0 Mil).

Knight Therapeutics's annual Long-Term Debt increased from Dec. 2021 (C$9.3 Mil) to Dec. 2022 (C$52.4 Mil) but then declined from Dec. 2022 (C$52.4 Mil) to Dec. 2023 (C$44.0 Mil).

Knight Therapeutics Long-Term Debt Historical Data

The historical data trend for Knight Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Long-Term Debt Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

5.02

9.27

52.40

44.02

Knight Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															52.40	55.04	51.36	49.68	44.02

Knight Therapeutics (TSX:GUD) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Knight Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics (TSX:GUD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Executives

Sime Armoyan

10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines